A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

Administered By

Awarded By

Contributors

Start/End

  • November 1, 2021 - October 31, 2029